Drugs / ABBV-011
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03639194 | Oct 2018 → Jan 2024 | small cell lung carcinoma | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-011 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03639194 ↗ |
| Route | Intravenous | “ABBV-011 via intravenous administration at various doses and dosing regimens until the maximum tolerated dose and/or the recommended Part B dose(s) is declared.” NCT03639194 ↗ |